IM Ketorolac vs Cambia for the Acute Treatment of Severe Migraine

• Status: Unknown status
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This research will be conducted to see if the oral drug Cambia is as effective in relieving severe migraine headaches as the injectable drug ketorolac.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Scripps Health
• Collaborator: Depomed
• Treatments: Diclofenac; Ketorolac; Ketorolac Tromethamine; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Patients who meet IHS criteria for migraine

• Age 18 to 65

• At least 2 migraine attacks per month

• Able to give written consent

• Willing to complete the entire course of the study

• Current headache duration greater than or equal to 36 hours

Exclusion Criteria:

• Pregnant or nursing

• Significant medical or psychiatric disease

• History of gastritis, gastric ulcer, GI bleed

• Renal insufficiency

• Hepatic insufficiency

• History of opioid dependence within the last 10 years or currently

• Any current or prior use of DICLOFENAC POTASSIUM POWDER FOR ORAL SOLUTION (CAMBIA)

• Past allergic reaction to DICLOFENAC or other NSAIDs